

Mercia Asset Management

Life sciences helping the COVID-19 fight

Portfolio update

Investment companies

Life sciences is one of Mercia's areas of focus and investment expertise. Seven of Mercia's top 20 holdings at 31 March 2020 were in life sciences, valued at £29m in aggregate or 33% of total portfolio value (all of which had originated through Mercia's third-party managed funds), with another c 40 earlier-stage life sciences investments across its third-party managed funds. COVID-19 has accelerated the opportunity for a new generation of novel and recombinant vaccines. This explosion of potential new treatments will require new diagnostics and bio-manufacturing support to scale supply once they are approved. These are areas where Mercia is already invested.

Period end	Net cash* (£m)	Direct investments (£m)	FUM (£m)	NAV (£m)	NAV per share (p)	P/NAV (x)
03/17	59.6	52.0	336.5	121.4	40.4	0.53
03/18	49.4	66.1	400.0	123.5	40.7	0.53
03/19	29.8	87.7	381.0	126.1	41.6	0.51
03/20	30.2	87.5	658.0	141.5	32.1	0.67

Note: *Includes liquid securities but not funds held on behalf of EIS investors.

Mercia remains well funded

Mercia ended FY20 with £30m of unrestricted balance sheet cash and short-term liquidity investments included within total liquidity of c £320m across all asset classes. This means it is in a strong position to continue to deploy capital, both through its managed funds as well as in direct investments on its balance sheet.

Overall beneficial impact from COVID-19

Although Mercia's engineering/materials related investments have experienced the most negative impact from COVID-19, some of these have started to show signs of recovery. However, 80% of Mercia's direct investment portfolio is in sectors that have seen positive benefits from COVID-19, such as life sciences (33% of the direct investment portfolio) and software (49% of the direct investment portfolio), providing a strong underpinning for FY21.

Valuation: 0.67x NAV + £20m for MFM

Mercia's shares continue to trade at a discount to NAV (0.67x), even before considering the embedded value of Mercia's fund management operations (MFM), which we estimate could be worth an additional £20m (c 4.5p per share) on top of NAV. Catalysts for a re-rating include further scaling of the business, commercialisation of the direct investment portfolio and/or further successful exits similar to that of The Native Antigen Company announced in July 2020.

14 October 2020

Price **21.4p**
Market cap **£94m**

Net cash (£m) at 31 March 2020	30.2
Shares in issue	440.1m
Free float	68.6%
Code	MERC
Primary exchange	AIM
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	18.9	4.4	(25.4)
Rel (local)	19.4	6.6	(11.2)
52-week high/low	33.5p	13.8p	

Business description

Mercia Asset Management is a regionally focused specialist asset manager. Its stated intent is to become the leading regional provider of supportive balance sheet, venture, private equity and debt capital in transaction sizes typically below £10m.

Next event

Half-year results	December 2020
-------------------	---------------

Analysts

Richard Williamson	+44 (0)20 3077 5700
Rob Murphy	+44 (0)20 3077 5700

tech@edisongroup.com

[Edison profile page](#)

Mercia Asset Management is a research client of Edison Investment Research Limited

Mercia's life sciences portfolio

COVID-19 presses the accelerator

For many years, life sciences has been a significant growth sector globally, with new technologies and techniques being applied across numerous specialist fields. The UK is a global leader in life sciences, with new businesses being set-up or spun out of universities across the breadth of the country. COVID-19, and the search for better diagnostics, vaccines and bio-manufacturing, has delivered a boost for the sector, with momentum anticipated to continue even once new vaccines have been found.

Mercia has a 15-year track record in the life sciences sector, which is not surprising given most of the UK's fast-growing life sciences' industry is based in the UK's regions and, as such, life sciences is one of Mercia's three principal sectors.

Mercia and its life sciences portfolio companies have issued a series of announcements in 2020 (including the sale of The Native Antigen Company announced in July 2020):

- In early April, two of Mercia's direct portfolio companies, The Native Antigen Company and Oxford Genetics (OXGENE), announced the formation of a new strategic partnership to scale up COVID-19 antigen production. This was followed in early May by the announcement of a £3m funding round into OXGENE, with Mercia investing a further £1m alongside Canaccord Genuity Wealth Management. OXGENE's technology accelerates the design, discovery and manufacture of new biologics.
- 14 May 2020 – Medherant, a transdermal drug delivery company, announced a partnership agreement with Cycle Pharmaceuticals to develop new products using Medherant's proprietary TEPI Patch technology. Under the agreement, Medherant will receive upfront payments for each candidate drug targeted and royalty payments on future product sales.
- 1 July 2020 – MIP Diagnostics completed a £5.1m funding round to scale production of its polymer antibodies, with Mercia committing £0.5m alongside the Business Growth Fund, Downing Ventures, Calculus Capital and MIP management.
- 9 July 2020 – Mercia announced the sale of The Native Antigen Company for up to £18m in cash, with management expecting to realise £5.2m (1.2p per share) for the group's 29.4% direct investment. The Native Antigen Company was held at £3.5m on the balance sheet at 31 March 2020, with the sale representing a fair value gain of up to £1.9m – an 8.4x return on Mercia's initial December 2014 direct investment and an internal rate of return (IRR) of 65%.

Given the significant progress made in FY20, Mercia provided an update on its life sciences portfolio on 18 September 2020 to highlight the unrecognised value in the portfolio.

Life sciences in the context of the overall portfolio

Life sciences is one of Mercia's areas of focus and investment expertise.

Seven of Mercia's top 20 holdings at 31 March 2020 were in life sciences, valued at £29m in aggregate or 33% of total portfolio value (all of which had originated through Mercia's third-party managed funds) with another c 40 earlier-stage investments across its third-party managed funds. In FY20 to date, £4.2m has been invested into six of Mercia's direct life sciences investments, with a further £1.6m invested in the sector through Mercia's managed funds.

At 31 March 2020, Mercia held £30m of unrestricted cash and short-term liquidity investments within total liquidity of c £320m across all asset classes. This financial firepower means Mercia is in

a strong position to continue to deploy capital through its managed funds as well as directly from its balance sheet.

Although Mercia's engineering/materials related investments have experienced the most negative impact from COVID-19, a number of these have started to show signs of recovery over the past few months. However, over 80% of the portfolio is in sectors that have responded positively to the COVID-19 pandemic, such as life sciences (a third of the direct investment portfolio), software and digital entertainment (49% of the direct investment portfolio), providing a strong underpinning for FY21.

Exhibit 1: Direct investment portfolio							
£000s	Net value 1 April 2019	Net cash invested FY20	Fair value change FY20	Net value 31 March 2020	Fair value change FY20	Mercia's holding at 31 March 2020	Estimated enterprise value** at 31 March 2020
	£000s	£000s	£000s	£000s	%	%	£000s
nDreams	15,120	1,000	-	16,120	-	36.4	44,300
OXGENE	10,161	-	1,582	11,743	16	30.2	38,900
Intechnica	6,677	500	-	7,177	-	27.5	26,100
Medherant	5,205	1,500	-	6,705	-	30.1	22,300
Voxpopme	3,026	2,000	1,004	6,030	33	17.1	35,300
Ton UK (Intelligent Positioning)	5,473	400	(1,519)	4,354	(28)	28.2	15,400
Impression Technologies	5,381	2,000	(3,087)	4,294	(57)	25.9	16,600
Faradion	3,525	500	-	4,025	-	15.6	25,800
Warwick Acoustics	7,904	1,065	(5,313)	3,656	(67)	52.9	6,900
The Native Antigen Company*	2,863	-	630	3,493	22	29.4	11,900
Soccer Manager	2,099	300	135	2,534	6	34.8	7,300
Edge Case Games	2,300	-	-	2,300	-	21.2	10,800
Locate Bio	500	1,750	-	2,250	-	17.4	12,900
VirtTrade (Avid Games)	3,938	550	(2,288)	2,200	(58)	25.8	8,500
PsiOxus Therapeutics	2,377	160	(344)	2,193	(15)	1.4	156,600
sureCore	1,834	333	-	2,167	-	22.0	9,900
W2 Global Data Solutions	2,000	-	-	2,000	-	15.2	13,200
Eyoto Group	1,755	875	(878)	1,752	(50)	15.7	11,200
One Touch Apps (Clear Review)	-	500	-	500	-	3.9	12,800
Concepta	1,133	750	(1,408)	475	(124)	22.4	2,100
Other direct investments	4,388	1,473	(4,358)	1,503			
Total	87,659	15,656	(15,844)	87,471			

Source: Mercia. Note: Excludes post year-end investments. *The sale of The Native Antigen Company was announced at the start of July 2020 for up to £18m in cash, a c 50% uplift on fair value. **Enterprise values are estimated from fully diluted shareholding percentages.

Update on life sciences portfolio

We have provided a summary of Mercia's seven direct investments in Exhibit 3, but Mercia's full announcement, including commentary on the managed fund investments in the sector can be found [here](#).

We have also recorded an Edison TV interview, where Dr Mark Payton (CEO with responsibility for OXGENE, Medherant and MIPs), Peter Dines (COO and previous head of life sciences with responsibility for Sense Bio, Locate Bio, The Native Antigen Company and Axis) and Dr Mark Wyatt (investment director with responsibility for Abingdon Health) discuss Mercia's approach to investment in the life sciences sector, the impact of COVID-19 and what this might mean for Mercia's future investment strategy in life sciences.

Exhibit 2: Management interview video - Mercia's approach to life sciences

Source: Edison Investment Research

Mercia's approach to investment in life sciences

Mercia's investment track record in the life sciences sector stretches back over 15 years. Today, Mercia manages a portfolio of over 400 businesses through its venture capital, private equity and debt managed funds, of which c 10% by number are in the life sciences sector. Together with its focus on the regions and wide network of offices (eight locations around the country), Mercia has privileged, early access to deal flow from the regions. This provides a filtered pipeline of future direct investments at the parent level. It is notable that all seven life science investments in Mercia's top 20 holdings originated through its managed funds.

It is also worth making the point that life sciences is a very broad investment category. Within the Mercia senior management team, Dr Mark Payton, Peter Dines and Dr Mark Wyatt, all have industry expertise in the sector as well as a long-term investment track record. However, given the breadth of the sector, the team benefits from Mercia's collective network of contacts to validate and undertake diligence on potential investment opportunities in specific fields. Mercia has built relationships with 19 university partners to support the business. With over 40 life sciences companies in the group, Mercia also has access to a network of non-executive directors, each a source of potential deal flow and sector contacts.

Given its financial resources, Mercia targets businesses with relatively modest capital needs, typically up to c £20m in total across multiple rounds. Given that leading biotechs often raise hundreds of millions of dollars of pure risk capital, this constrained access to capital means Mercia tends to look for opportunities in relatively unloved sectors such as diagnostics, medtech (although recent valuations have been picking up) and improvements in bio-manufacturing production.

COVID-19 has accelerated investment in life sciences

COVID-19 has also had a major impact. As has happened with the acceleration of the transition to a digital economy, COVID-19 has also significantly accelerated vaccine development, with five years of normal development time being compressed into just months. In the last 20 years, no more than a handful of new vaccines have been approved for use on the public. However, in response to COVID-19, c 40 new vaccines are under clinical development, with six in Phase III trials, of which five are based on novel recombinant technologies. Another 100+ are in pre-clinical trials.

For Mercia, COVID-19 has accelerated the opportunity for a new generation of novel and recombinant vaccines. There is unlikely to be a single vaccine, with multiple vaccines a more probable outcome to be used amongst different groups by governments around the world. This explosion of potential new treatments will all require new diagnostics to measure their efficacy, as well as bio-manufacturing support to scale supply once they are approved. These are areas where Mercia has invested.

Exhibit 3: Mercia's direct investments in life sciences

OXGENE

Stage: Series B	Bio-manufacturing – gene therapy, gene editing and antibody discovery
Valuation: £38.9m	Direct stake: 30.2% fully diluted
Mercia direct funding as at 31/3/20: £5.1m	Managed funds: c 10% fully diluted stake
Strategic partnership with Fujifilm Diosynth Biotechnologies	100%+ annual revenue growth (FY18–20)
Co-investors: Canaccord Genuity Wealth Management	Indirect spin-out from Oxford University

Medherant

Stage: Series A	Medtech – transdermal drug-in-adhesive patches
Valuation: £19.2m	Direct stake: 30.1% fully diluted
Mercia direct funding as at 31/3/20: £5.2m	Managed funds: c 16% fully diluted stake
Co-investors: Cycle Pharma, Innovate UK	University of Warwick
In June 2020, the company completed a £2.8m syndicated round, with Mercia investing £1.4m	In May 2020, Medherant announced a strategic partnership with Cycle Pharma to commercialise the TEPI Patch® technology

Locate Bio

Stage: Seed	Orthobiologics – therapies include bone protein to overcome lower back pain and biological renewal of the intervertebral disc
Valuation: £12.9m	Direct stake: 17.4% fully diluted
Mercia direct funding as at 31/3/20: £2.3m	Managed funds: c 17% fully diluted stake
New CEO appointed (ex ApaTech)	University of Nottingham
Co-investors: Wellcome Trust, Heraeus Medical, Future Fund	In July 2020, Locate secured a syndicated investment of £2.5m of which Mercia made a direct investment of £0.8m.

MIP Diagnostics

Stage: Series A	Diagnostics – development and manufacture of synthetic affinity reagents, polymers designed to bind to specific target molecules for detection, purification or extraction
Valuation: £12.9m	Direct stake: 3.3% fully diluted
Mercia direct funding as at 31/3/20: £0.3m	Managed funds: c 30% fully diluted stake
Co-investors: Downing, Calculus, BGF	University of Leicester
£5.1m syndicated funding round in July 2020 to accelerate global expansion	Partnership with Stream Bio to develop a rapid COVID-19 viral infection detection assay

The Native Antigen Company

Stage: Exited	Diagnostics – leading producer of infectious disease reagents that include antigens for COVID-19 antibody test kits
Valuation: £18.0m (50% premium to book value)	Direct stake: 29.4% fully diluted
Mercia direct funding as at 31/3/20: £0.1m	Managed funds: c 30% fully diluted stake
Co-investors: Angel investors	University of Birmingham
Sold to global life sciences tools company LGC in July 2020	The exit generated an 8.4x return and a 65% IRR on Mercia's original direct investment and a 12.1x return, a 31% fund IRR, on Mercia's blended managed fund investments

Source: Edison Investment Research, Crunchbase, Mercia Asset Management

Exhibit 4: Financial summary

	£'000	2015	2016	2017	2018	2019	2020
Year end 31 March		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
INCOME STATEMENT							
Revenue		508	1,755	6,660	10,197	10,675	12,747
Cost of Sales		(10)	(79)	(92)	0	0	0
Gross Profit		498	1,676	6,568	10,197	10,675	12,747
Operating costs		(1,495)	(4,011)	(9,051)	(10,633)	(12,115)	(12,661)
Fair value changes		3,934	896	4,268	2,823	3,916	(15,844)
Realised gains		0	0	839	871	0	0
Normalised operating profit		2,937	(1,439)	2,624	3,258	2,476	(15,758)
Amortisation of acquired intangibles		0	(17)	(301)	(301)	(301)	(852)
Exceptionals		(1,018)	(372)	(1,125)	(1,125)	0	(695)
Share-based payments		(44)	(230)	(395)	(497)	(171)	(528)
Reported operating profit		1,875	(2,058)	803	1,335	2,004	(17,833)
Net Interest		93	361	186	274	562	220
Joint ventures & associates (post tax)		0	0	0	0	0	0
Profit Before Tax (norm)		3,030	(1,078)	2,810	3,532	3,038	(15,538)
Profit Before Tax (reported)		1,968	(1,697)	989	1,609	2,566	(17,613)
Reported tax		0	0	54	54	54	159
Profit After Tax (norm)		3,030	(1,078)	2,810	3,532	3,038	(15,538)
Profit After Tax (reported)		1,968	(1,697)	1,043	1,663	2,620	(17,454)
Minority interests		0	0	0	0	0	0
Discontinued operations		0	0	0	0	0	0
Net income (normalised)		3,030	(1,078)	2,810	3,532	3,038	(15,538)
Net income (reported)		1,968	(1,697)	1,043	1,663	2,620	(17,454)
Basic average number of shares outstanding (m)		212	212	224	302	303	341
EPS – basic normalised (p)		1.43	(0.51)	1.26	1.17	1.00	(4.55)
EPS – diluted normalised (p)		1.43	(0.51)	1.21	1.13	1.00	(4.55)
EPS – basic reported (p)		0.93	(0.80)	0.47	0.55	0.86	(5.11)
Dividend (p)		0.00	0.00	0.00	0.00	0.00	0.00
Revenue growth (%)		(29.7)	245.5	279.5	53.1	4.7	19.4
Gross Margin (%)		98.0	95.5	98.6	100.0	100.0	100.0
Normalised Operating Margin		578.1	-82.0	39.4	32.0	23.2	-123.6
BALANCE SHEET							
Fixed Assets		27,121	50,103	63,693	77,428	98,724	124,899
Intangible Assets		2,455	11,815	11,514	11,213	10,912	36,705
Tangible Assets		49	145	151	145	153	125
Right of use assets		0	0	0	0	0	598
Investments & other		24,617	38,143	52,028	66,070	87,659	87,471
Current Assets		54,349	31,730	64,576	53,965	31,180	31,951
Stocks		0	0	0	0	0	0
Debtors		716	798	747	1,057	782	1,298
Cash & cash equivalents		23,633	20,932	28,829	42,908	25,210	24,438
Short term liquidity investments		30,000	10,000	35,000	10,000	5,188	6,215
Current Liabilities		(631)	(1,521)	(6,698)	(7,760)	(3,730)	(6,659)
Creditors		(631)	(1,521)	(6,698)	(7,760)	(3,730)	(4,805)
Tax and social security		0	0	0	0	0	0
Lease liabilities		0	0	0	0	0	(118)
Short term borrowings		0	0	0	0	0	0
Other (incl deferred consideration)		0	0	0	0	0	(1,736)
Long Term Liabilities		0	(271)	(217)	(163)	(109)	(8,731)
Long term borrowings		0	0	0	0	0	0
Lease liabilities		0	0	0	0	0	(473)
Other long term liabilities		0	(271)	(217)	(163)	(109)	(8,258)
Net Assets		80,839	80,041	121,354	123,470	126,065	141,460
Minority interests		0	0	0	0	0	0
Shareholders' equity		80,839	80,041	121,354	123,470	126,065	141,460
NAV per share (p)		38.13	37.46	40.37	40.71	41.56	32.14
CASH FLOW							
Op Cash Flow before WC and tax		2,943	(1,406)	2,700	3,339	2,560	(15,685)
Working capital		(20)	650	5,250	(87)	(3,724)	533
Exceptional & other		(4,952)	(1,268)	(5,107)	(3,694)	(3,916)	15,149
Depreciation of right-of-use assets		0	0	0	0	0	139
Tax		0	0	0	0	0	0
Net operating cash flow		(2,029)	(2,024)	2,843	(442)	(5,080)	136
Capex		(27)	(113)	(82)	(75)	(92)	(45)
Acquisitions/disposals		(11,563)	(20,939)	(8,779)	(10,664)	(17,673)	(28,056)
Net interest		22	397	165	260	531	245
Equity financing		67,230	(22)	38,750	0	(196)	30,000
Dividends		0	0	0	0	0	0
Other		(30,000)	20,000	(25,000)	25,000	4,812	(3,052)
Net Cash Flow		23,633	(2,701)	7,897	14,079	(17,698)	(772)
Opening net debt/(cash)		(39)	(23,633)	(20,932)	(28,829)	(42,908)	(25,210)
FX		0	0	0	0	0	0
Other non-cash movements		(39)	0	0	0	0	0
Closing net debt/(cash)		(23,633)	(20,932)	(28,829)	(42,908)	(25,210)	(24,438)
Closing net debt/ (cash) inc short-term liquidity investments (not EIS)		(53,633)	(30,932)	(59,601)	(49,435)	(29,769)	(30,186)

Source: Mercia Asset Management accounts

General disclaimer and copyright

This report has been commissioned by Mercia Asset Management and prepared and issued by Edison, in consideration of a fee payable by Mercia Asset Management. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
